Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16435008 | 0.74 | ACACB (0.43) | ACACBPKMKDM4EMEN1KMT2A | |
| SCHEMBL16448857 | 0.72 | ACACB (0.38) | ACACBMEN1KMT2A | |
| SCHEMBL12787337 | 0.71 | ACACB (0.41) | ACACBPKMKDM4EMEN1KMT2A | |
| SCHEMBL1285654 | 0.68 | ACACB (0.39) | ACACBPKMKDM4EMEN1KMT2A | |
| SCHEMBL10187968 | 0.68 | ACACB (0.39) | ACACBPKMKDM4EMEN1KMT2A | |
| SCHEMBL1286093 | 0.68 | KDR (0.44) | ACACBPKMKDM4EMEN1KMT2A | |
| SCHEMBL1285780 | 0.68 | ALDH1A1 (0.41) | ACACBPKMKDM4EMEN1KMT2A | |
| SCHEMBL1286064 | 0.68 | ALDH1A1 (0.39) | ACACBPKMMEN1KMT2A | |
| SCHEMBL1285630 | 0.66 | NPC1 (0.40) | ACACBPKMKDM4EKMT2A | |
| SCHEMBL29951002 | 0.65 | ACACB (0.40) | ACACBPKMKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088755-A1 | Novel Compounds | SLC26A4, F12, SLCO1B3 | ACACB 4356/4885PKM 942/4885KDM4E 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.